Skip to main content
Back to feed
MarketsSingle-sourceLowDeveloping
2.1

US biotech Axiom Biosciences targets $200M Hong Kong IPO by 2027

Axiom Biosciences plans a primary listing in Hong Kong to raise $200 million for AI-driven neonatal brain injury therapies, with a subsequent US secondary listing in 2029. The move highlights a trend of AI-focused medical firms seeking capital in Asian markets despite ongoing US-China geopolitical tensions.

South China Morning Post2 days agoUS, CN, HKCredibility 34%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#biotech#ipo#ai#capital markets#healthcare

Locations

Hong Kong

Entities

countrycountry
Source

Related signals

8 found